Fujifilm will also showcase its Aspire Cristalle mammography system in Booth #145 at NCoBC from April 9-13, 2016.
“At Fujifilm, our goal is to support patient awareness, early detection and patient centric care,” said Rob Fabrizio, director of marketing and product development, Digital X-Ray and Women’s Health, FUJIFILM Medical Systems U.S.A., Inc. “We’re proud to sponsor the keynote presentation at NCoBC emphasizing the critical role of patient and provider awareness of breast type and their corresponding risk factors in screening for breast cancer.”
Dr. Cappello’s keynote remarks—“Why I Talk to Strangers About My Breasts”—will focus on breast density ramifications and legislation. The impact of dense breast tissue remained exclusively in the medical journals for more than a decade until, in 2009, through Dr. Cappello’s relentless activism, Connecticut, her home state, became the first state to mandate the reporting of dense breast tissue to the patient through the mammography report. From patient to advocate, Dr. Cappello launched Are You Dense, Inc. and Are You Dense Advocacy, Inc., both work together as a global grassroots density education and reporting movement. Her inspiring story, conveyed with passion and humor, illustrates how one person can make a potential life-saving difference in women’s health.
Dr. Cappello will also be available at the Fujifilm booth #145 for informal Q&A sessions on Saturday, April 9th from 10:15am-10:45am and 11:45am-1:00pm.
“It is my personal priority—and the mission of my organizations— to ensure that patients, policymakers and health-care providers understand the significance of dense breast tissue and the importance of regular, reliable screening,” said Dr. Cappello. “I am very grateful to have the support of Fujifilm, a company that clearly understands how educational efforts and awareness-building can help save lives.”
Fujifilm’s Aspire Cristalle mammography system features an innovative hexagonal close pattern (HCP) detector design, engineered for higher acquisition efficiency, to enhance detail for improved low dose performance. The result is sharper images with gentler dose to the patient. Additionally, Aspire Cristalle incorporates a patient calming design and Fujifilm’s patented Comfort Paddle which is designed to make the most physically unpleasant part of mammograms, noticeably more comfortable for the patient.
In November 2015, Fujifilm submitted to the U.S. Food and Drug Administration (FDA) the second module of its premarket approval (PMA) application for Digital Breast Tomosynthesis (DBT)*, as an optional upgrade for the Aspire Cristalle mammography system.
